N. Vasudev
Molecular Biology · 2014
A researcher in the Science corpus: 1 paper; trusts 5 researchers and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Molecular Biology — 44 citations into it; #11,050 of 17,773 by trust here, #16,527 by citations
- Oncology — 33 citations into it; #865 of 1,698 by trust here, #1,608 by citations
- Cancer Research — 27 citations into it
Whom N. Vasudev trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- Rakesh K. Jain
- Peter Carmeliet
- John M. L. Ebos
- E. Raymond
- R. Kerbel
- G. Bergers
- D. Hicklin
- Raghu Kalluri
- J. Joyce
- Michele De Palma
Who trusts N. Vasudev overall
Papers from N. Vasudev's perspective
Ordered by how strongly the researchers N. Vasudev trusts endorse each paper. Same corpus, a different order for every researcher.
- Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. (New England Journal of Medicine)
- Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. (New England Journal of Medicine)
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis (Cancer Cell)
- Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy (Nature Medicine)
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy (Science)
- Molecular mechanisms and clinical applications of angiogenesis (Nature)
- Microenvironmental regulation of metastasis (Nature Reviews. Cancer)
- Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. (Cancer Cell)
- Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. (Cell)
- Glioblastoma stem-like cells give rise to tumour endothelium (Nature)